nodes	percent_of_prediction	percent_of_DWPC	metapath
Glyburide—ABCC3—Cyclosporine—psoriasis	0.0425	0.06	CbGbCtD
Glyburide—ABCB11—Cyclosporine—psoriasis	0.0367	0.0518	CbGbCtD
Glyburide—ALB—Acitretin—psoriasis	0.0339	0.0479	CbGbCtD
Glyburide—CFTR—sweat gland—psoriasis	0.0302	0.49	CbGeAlD
Glyburide—ABCC1—Cyclosporine—psoriasis	0.0261	0.0368	CbGbCtD
Glyburide—SLCO1A2—Prednisolone—psoriasis	0.026	0.0367	CbGbCtD
Glyburide—ABCC2—Mycophenolate mofetil—psoriasis	0.0255	0.036	CbGbCtD
Glyburide—CFTR—sweat—psoriasis	0.0253	0.41	CbGeAlD
Glyburide—SLCO1A2—Hydrocortisone—psoriasis	0.0247	0.0348	CbGbCtD
Glyburide—SLCO1A2—Prednisone—psoriasis	0.0246	0.0347	CbGbCtD
Glyburide—ABCB11—Dexamethasone—psoriasis	0.0242	0.0341	CbGbCtD
Glyburide—SLCO1A2—Cyclosporine—psoriasis	0.0233	0.0329	CbGbCtD
Glyburide—ABCG2—Mycophenolate mofetil—psoriasis	0.023	0.0325	CbGbCtD
Glyburide—ABCC3—Methotrexate—psoriasis	0.0225	0.0317	CbGbCtD
Glyburide—ABCC2—Cyclosporine—psoriasis	0.0193	0.0272	CbGbCtD
Glyburide—ABCG2—Hydrocortisone—psoriasis	0.0185	0.0261	CbGbCtD
Glyburide—SLC22A7—Methotrexate—psoriasis	0.0176	0.0248	CbGbCtD
Glyburide—ABCG2—Cyclosporine—psoriasis	0.0175	0.0246	CbGbCtD
Glyburide—ALB—Mycophenolate mofetil—psoriasis	0.0159	0.0224	CbGbCtD
Glyburide—SLCO1A2—Dexamethasone—psoriasis	0.0153	0.0216	CbGbCtD
Glyburide—SLC22A6—Cyclosporine—psoriasis	0.0141	0.0199	CbGbCtD
Glyburide—ABCC1—Methotrexate—psoriasis	0.0138	0.0195	CbGbCtD
Glyburide—ABCC2—Dexamethasone—psoriasis	0.0127	0.0179	CbGbCtD
Glyburide—ALB—Prednisone—psoriasis	0.0127	0.0179	CbGbCtD
Glyburide—SLCO1A2—Methotrexate—psoriasis	0.0123	0.0174	CbGbCtD
Glyburide—CYP2C19—Cholecalciferol—psoriasis	0.0119	0.0168	CbGbCtD
Glyburide—ABCG2—Dexamethasone—psoriasis	0.0115	0.0162	CbGbCtD
Glyburide—CYP3A4—Calcitriol—psoriasis	0.0111	0.0157	CbGbCtD
Glyburide—ABCC2—Methotrexate—psoriasis	0.0102	0.0144	CbGbCtD
Glyburide—CYP2C9—Cholecalciferol—psoriasis	0.00987	0.0139	CbGbCtD
Glyburide—ABCG2—Methotrexate—psoriasis	0.00924	0.013	CbGbCtD
Glyburide—CYP3A4—Methoxsalen—psoriasis	0.00867	0.0122	CbGbCtD
Glyburide—ABCB1—Mycophenolate mofetil—psoriasis	0.00831	0.0117	CbGbCtD
Glyburide—CYP2C19—Prednisone—psoriasis	0.00823	0.0116	CbGbCtD
Glyburide—CYP2C19—Cyclosporine—psoriasis	0.0078	0.011	CbGbCtD
Glyburide—SLC22A6—Methotrexate—psoriasis	0.00748	0.0106	CbGbCtD
Glyburide—ABCB1—Betamethasone—psoriasis	0.00713	0.0101	CbGbCtD
Glyburide—ABCB1—Prednisolone—psoriasis	0.00703	0.00992	CbGbCtD
Glyburide—ABCB1—Hydrocortisone—psoriasis	0.00667	0.00941	CbGbCtD
Glyburide—ABCB1—Prednisone—psoriasis	0.00664	0.00937	CbGbCtD
Glyburide—CYP2C9—Cyclosporine—psoriasis	0.00649	0.00915	CbGbCtD
Glyburide—ALB—Methotrexate—psoriasis	0.00637	0.00899	CbGbCtD
Glyburide—ABCB1—Cyclosporine—psoriasis	0.0063	0.00888	CbGbCtD
Glyburide—CYP3A4—Cholecalciferol—psoriasis	0.00574	0.0081	CbGbCtD
Glyburide—CYP2C19—Dexamethasone—psoriasis	0.00514	0.00725	CbGbCtD
Glyburide—CYP3A4—Mycophenolate mofetil—psoriasis	0.00498	0.00702	CbGbCtD
Glyburide—CYP3A4—Triamcinolone—psoriasis	0.00498	0.00702	CbGbCtD
Glyburide—CYP2C9—Dexamethasone—psoriasis	0.00427	0.00603	CbGbCtD
Glyburide—CYP3A4—Betamethasone—psoriasis	0.00427	0.00602	CbGbCtD
Glyburide—CYP3A4—Prednisolone—psoriasis	0.00421	0.00594	CbGbCtD
Glyburide—ABCB1—Dexamethasone—psoriasis	0.00415	0.00585	CbGbCtD
Glyburide—CYP3A4—Hydrocortisone—psoriasis	0.00399	0.00564	CbGbCtD
Glyburide—CYP3A4—Prednisone—psoriasis	0.00398	0.00561	CbGbCtD
Glyburide—CYP3A4—Cyclosporine—psoriasis	0.00377	0.00532	CbGbCtD
Glyburide—ABCB1—Methotrexate—psoriasis	0.00333	0.0047	CbGbCtD
Glyburide—CYP3A4—Dexamethasone—psoriasis	0.00248	0.0035	CbGbCtD
Glyburide—ABCA1—skin of body—psoriasis	0.00191	0.031	CbGeAlD
Glyburide—Gliclazide—VEGFA—psoriasis	0.00165	0.429	CrCbGaD
Glyburide—CPT1A—tendon—psoriasis	0.00156	0.0254	CbGeAlD
Glyburide—Glipizide—PPARG—psoriasis	0.00127	0.33	CrCbGaD
Glyburide—KCNJ11—tendon—psoriasis	0.000928	0.0151	CbGeAlD
Glyburide—Bezafibrate—PPARG—psoriasis	0.000924	0.241	CrCbGaD
Glyburide—SLCO2B1—tendon—psoriasis	0.000669	0.0109	CbGeAlD
Glyburide—ABCC2—tendon—psoriasis	0.000573	0.00931	CbGeAlD
Glyburide—ABCC1—tendon—psoriasis	0.000505	0.0082	CbGeAlD
Glyburide—Oedema—Mycophenolate mofetil—psoriasis	0.000149	0.00082	CcSEcCtD
Glyburide—Hyperhidrosis—Cyclosporine—psoriasis	0.000147	0.000812	CcSEcCtD
Glyburide—Convulsion—Prednisolone—psoriasis	0.000147	0.000812	CcSEcCtD
Glyburide—Eosinophilia—Methotrexate—psoriasis	0.000147	0.000809	CcSEcCtD
Glyburide—Shock—Mycophenolate mofetil—psoriasis	0.000146	0.000807	CcSEcCtD
Glyburide—Nervous system disorder—Mycophenolate mofetil—psoriasis	0.000146	0.000804	CcSEcCtD
Glyburide—Thrombocytopenia—Mycophenolate mofetil—psoriasis	0.000145	0.000803	CcSEcCtD
Glyburide—Anorexia—Cyclosporine—psoriasis	0.000145	0.000801	CcSEcCtD
Glyburide—Pancreatitis—Methotrexate—psoriasis	0.000145	0.000801	CcSEcCtD
Glyburide—Alopecia—Betamethasone—psoriasis	0.000144	0.000794	CcSEcCtD
Glyburide—Alopecia—Dexamethasone—psoriasis	0.000144	0.000794	CcSEcCtD
Glyburide—Convulsion—Hydrocortisone—psoriasis	0.000144	0.000793	CcSEcCtD
Glyburide—Hyperhidrosis—Mycophenolate mofetil—psoriasis	0.000144	0.000792	CcSEcCtD
Glyburide—Vomiting—Hydroxyurea—psoriasis	0.000143	0.000789	CcSEcCtD
Glyburide—Angioedema—Triamcinolone—psoriasis	0.000143	0.000787	CcSEcCtD
Glyburide—Rash—Hydroxyurea—psoriasis	0.000142	0.000782	CcSEcCtD
Glyburide—Erythema—Betamethasone—psoriasis	0.000142	0.000782	CcSEcCtD
Glyburide—Erythema—Dexamethasone—psoriasis	0.000142	0.000782	CcSEcCtD
Glyburide—Anorexia—Mycophenolate mofetil—psoriasis	0.000142	0.000781	CcSEcCtD
Glyburide—Dermatitis—Hydroxyurea—psoriasis	0.000142	0.000781	CcSEcCtD
Glyburide—Myalgia—Hydrocortisone—psoriasis	0.000141	0.000779	CcSEcCtD
Glyburide—Headache—Hydroxyurea—psoriasis	0.000141	0.000777	CcSEcCtD
Glyburide—Pancytopenia—Methotrexate—psoriasis	0.000141	0.000776	CcSEcCtD
Glyburide—Hypotension—Mycophenolate mofetil—psoriasis	0.000139	0.000766	CcSEcCtD
Glyburide—Musculoskeletal discomfort—Cyclosporine—psoriasis	0.000139	0.000766	CcSEcCtD
Glyburide—Oedema—Prednisolone—psoriasis	0.000139	0.000765	CcSEcCtD
Glyburide—Paraesthesia—Cyclosporine—psoriasis	0.000137	0.000755	CcSEcCtD
Glyburide—Shock—Prednisolone—psoriasis	0.000136	0.000752	CcSEcCtD
Glyburide—Dyspnoea—Cyclosporine—psoriasis	0.000136	0.000749	CcSEcCtD
Glyburide—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	0.000135	0.000747	CcSEcCtD
Glyburide—Oedema—Hydrocortisone—psoriasis	0.000135	0.000747	CcSEcCtD
Glyburide—Convulsion—Triamcinolone—psoriasis	0.000135	0.000747	CcSEcCtD
Glyburide—Photosensitivity reaction—Methotrexate—psoriasis	0.000135	0.000745	CcSEcCtD
Glyburide—Asthenia—Mycophenolic acid—psoriasis	0.000135	0.000745	CcSEcCtD
Glyburide—Dyspepsia—Cyclosporine—psoriasis	0.000134	0.00074	CcSEcCtD
Glyburide—Hyperhidrosis—Prednisolone—psoriasis	0.000134	0.000739	CcSEcCtD
Glyburide—CPT1A—Metabolism—NDUFA5—psoriasis	0.000134	0.00301	CbGpPWpGaD
Glyburide—SLC22A7—SLC-mediated transmembrane transport—CP—psoriasis	0.000134	0.003	CbGpPWpGaD
Glyburide—Nausea—Hydroxyurea—psoriasis	0.000134	0.000737	CcSEcCtD
Glyburide—Paraesthesia—Mycophenolate mofetil—psoriasis	0.000133	0.000736	CcSEcCtD
Glyburide—Pruritus—Mycophenolic acid—psoriasis	0.000133	0.000735	CcSEcCtD
Glyburide—Shock—Hydrocortisone—psoriasis	0.000133	0.000735	CcSEcCtD
Glyburide—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000133	0.00298	CbGpPWpGaD
Glyburide—Myalgia—Triamcinolone—psoriasis	0.000133	0.000734	CcSEcCtD
Glyburide—Nervous system disorder—Hydrocortisone—psoriasis	0.000133	0.000732	CcSEcCtD
Glyburide—Eye disorder—Prednisone—psoriasis	0.000132	0.000731	CcSEcCtD
Glyburide—Dyspnoea—Mycophenolate mofetil—psoriasis	0.000132	0.000731	CcSEcCtD
Glyburide—Decreased appetite—Cyclosporine—psoriasis	0.000132	0.000731	CcSEcCtD
Glyburide—CPT1A—AMPK Signaling—TP53—psoriasis	0.000132	0.00295	CbGpPWpGaD
Glyburide—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000131	0.000726	CcSEcCtD
Glyburide—Hyperhidrosis—Hydrocortisone—psoriasis	0.000131	0.000722	CcSEcCtD
Glyburide—Dyspepsia—Mycophenolate mofetil—psoriasis	0.000131	0.000722	CcSEcCtD
Glyburide—CPT1A—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	0.000131	0.00293	CbGpPWpGaD
Glyburide—ABCA1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	0.000131	0.00293	CbGpPWpGaD
Glyburide—SLC22A7—Fluoropyrimidine Activity—TP53—psoriasis	0.00013	0.00291	CbGpPWpGaD
Glyburide—Angioedema—Betamethasone—psoriasis	0.000129	0.000714	CcSEcCtD
Glyburide—Angioedema—Dexamethasone—psoriasis	0.000129	0.000714	CcSEcCtD
Glyburide—Decreased appetite—Mycophenolate mofetil—psoriasis	0.000129	0.000713	CcSEcCtD
Glyburide—Anorexia—Hydrocortisone—psoriasis	0.000129	0.000712	CcSEcCtD
Glyburide—Diarrhoea—Mycophenolic acid—psoriasis	0.000129	0.000711	CcSEcCtD
Glyburide—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000128	0.000708	CcSEcCtD
Glyburide—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	0.000128	0.00287	CbGpPWpGaD
Glyburide—CPT1A—Circadian rythm related genes—NOS2—psoriasis	0.000128	0.00287	CbGpPWpGaD
Glyburide—Oedema—Triamcinolone—psoriasis	0.000127	0.000703	CcSEcCtD
Glyburide—Hypotension—Hydrocortisone—psoriasis	0.000126	0.000698	CcSEcCtD
Glyburide—SLC15A1—SLC-mediated transmembrane transport—CP—psoriasis	0.000126	0.00284	CbGpPWpGaD
Glyburide—Feeling abnormal—Cyclosporine—psoriasis	0.000126	0.000692	CcSEcCtD
Glyburide—Shock—Triamcinolone—psoriasis	0.000125	0.000692	CcSEcCtD
Glyburide—Alopecia—Prednisone—psoriasis	0.000125	0.000691	CcSEcCtD
Glyburide—ALB—Lipoprotein metabolism—APOE—psoriasis	0.000125	0.00281	CbGpPWpGaD
Glyburide—ABCA1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000125	0.0028	CbGpPWpGaD
Glyburide—CPT1A—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000125	0.0028	CbGpPWpGaD
Glyburide—ABCA1—Folate Metabolism—IL6—psoriasis	0.000125	0.0028	CbGpPWpGaD
Glyburide—Gastrointestinal pain—Cyclosporine—psoriasis	0.000125	0.000687	CcSEcCtD
Glyburide—Paraesthesia—Prednisolone—psoriasis	0.000124	0.000687	CcSEcCtD
Glyburide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000124	0.00278	CbGpPWpGaD
Glyburide—Malnutrition—Prednisone—psoriasis	0.000123	0.000681	CcSEcCtD
Glyburide—Erythema—Prednisone—psoriasis	0.000123	0.000681	CcSEcCtD
Glyburide—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000123	0.00068	CcSEcCtD
Glyburide—Hyperhidrosis—Triamcinolone—psoriasis	0.000123	0.00068	CcSEcCtD
Glyburide—Agranulocytosis—Methotrexate—psoriasis	0.000123	0.00068	CcSEcCtD
Glyburide—ABCA1—Selenium Micronutrient Network—TNF—psoriasis	0.000123	0.00276	CbGpPWpGaD
Glyburide—Convulsion—Betamethasone—psoriasis	0.000123	0.000677	CcSEcCtD
Glyburide—Convulsion—Dexamethasone—psoriasis	0.000123	0.000677	CcSEcCtD
Glyburide—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000122	0.000676	CcSEcCtD
Glyburide—Paraesthesia—Hydrocortisone—psoriasis	0.000122	0.000671	CcSEcCtD
Glyburide—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000121	0.00067	CcSEcCtD
Glyburide—Urticaria—Cyclosporine—psoriasis	0.000121	0.000668	CcSEcCtD
Glyburide—Myalgia—Betamethasone—psoriasis	0.000121	0.000666	CcSEcCtD
Glyburide—Myalgia—Dexamethasone—psoriasis	0.000121	0.000666	CcSEcCtD
Glyburide—Abdominal pain—Cyclosporine—psoriasis	0.00012	0.000664	CcSEcCtD
Glyburide—Vomiting—Mycophenolic acid—psoriasis	0.00012	0.00066	CcSEcCtD
Glyburide—CPT1A—Circadian rythm related genes—PPARG—psoriasis	0.000119	0.00268	CbGpPWpGaD
Glyburide—Dyspepsia—Hydrocortisone—psoriasis	0.000119	0.000657	CcSEcCtD
Glyburide—CYP2C19—Biological oxidations—CYP2S1—psoriasis	0.000119	0.00267	CbGpPWpGaD
Glyburide—Rash—Mycophenolic acid—psoriasis	0.000119	0.000655	CcSEcCtD
Glyburide—Dermatitis—Mycophenolic acid—psoriasis	0.000119	0.000654	CcSEcCtD
Glyburide—Hepatitis—Methotrexate—psoriasis	0.000118	0.000654	CcSEcCtD
Glyburide—Urticaria—Mycophenolate mofetil—psoriasis	0.000118	0.000651	CcSEcCtD
Glyburide—Headache—Mycophenolic acid—psoriasis	0.000118	0.000651	CcSEcCtD
Glyburide—Decreased appetite—Hydrocortisone—psoriasis	0.000118	0.000649	CcSEcCtD
Glyburide—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000117	0.000648	CcSEcCtD
Glyburide—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	0.000117	0.00264	CbGpPWpGaD
Glyburide—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000117	0.000645	CcSEcCtD
Glyburide—Vision blurred—Prednisone—psoriasis	0.000116	0.000642	CcSEcCtD
Glyburide—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.000116	0.000641	CcSEcCtD
Glyburide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000116	0.0026	CbGpPWpGaD
Glyburide—Oedema—Betamethasone—psoriasis	0.000116	0.000638	CcSEcCtD
Glyburide—Oedema—Dexamethasone—psoriasis	0.000116	0.000638	CcSEcCtD
Glyburide—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	0.000115	0.00259	CbGpPWpGaD
Glyburide—Paraesthesia—Triamcinolone—psoriasis	0.000114	0.000631	CcSEcCtD
Glyburide—Feeling abnormal—Prednisolone—psoriasis	0.000114	0.00063	CcSEcCtD
Glyburide—Visual impairment—Methotrexate—psoriasis	0.000114	0.00063	CcSEcCtD
Glyburide—Anaemia—Prednisone—psoriasis	0.000114	0.000629	CcSEcCtD
Glyburide—CPT1A—Metabolism—CYP2S1—psoriasis	0.000114	0.00256	CbGpPWpGaD
Glyburide—ABCA1—Metabolism—CYP2S1—psoriasis	0.000114	0.00256	CbGpPWpGaD
Glyburide—Shock—Dexamethasone—psoriasis	0.000114	0.000628	CcSEcCtD
Glyburide—Shock—Betamethasone—psoriasis	0.000114	0.000628	CcSEcCtD
Glyburide—Dyspnoea—Triamcinolone—psoriasis	0.000114	0.000627	CcSEcCtD
Glyburide—Nervous system disorder—Dexamethasone—psoriasis	0.000113	0.000626	CcSEcCtD
Glyburide—Nervous system disorder—Betamethasone—psoriasis	0.000113	0.000626	CcSEcCtD
Glyburide—Thrombocytopenia—Dexamethasone—psoriasis	0.000113	0.000625	CcSEcCtD
Glyburide—Thrombocytopenia—Betamethasone—psoriasis	0.000113	0.000625	CcSEcCtD
Glyburide—Angioedema—Prednisone—psoriasis	0.000113	0.000622	CcSEcCtD
Glyburide—Hypersensitivity—Cyclosporine—psoriasis	0.000112	0.000619	CcSEcCtD
Glyburide—Dyspepsia—Triamcinolone—psoriasis	0.000112	0.000619	CcSEcCtD
Glyburide—Nausea—Mycophenolic acid—psoriasis	0.000112	0.000617	CcSEcCtD
Glyburide—Hyperhidrosis—Betamethasone—psoriasis	0.000112	0.000617	CcSEcCtD
Glyburide—Hyperhidrosis—Dexamethasone—psoriasis	0.000112	0.000617	CcSEcCtD
Glyburide—CPT1A—SIDS Susceptibility Pathways—CXCL8—psoriasis	0.000112	0.00251	CbGpPWpGaD
Glyburide—Feeling abnormal—Hydrocortisone—psoriasis	0.000112	0.000615	CcSEcCtD
Glyburide—ABCC3—Fluoropyrimidine Activity—TP53—psoriasis	0.000111	0.00249	CbGpPWpGaD
Glyburide—Eye disorder—Methotrexate—psoriasis	0.000111	0.000611	CcSEcCtD
Glyburide—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000111	0.000611	CcSEcCtD
Glyburide—Anorexia—Betamethasone—psoriasis	0.00011	0.000608	CcSEcCtD
Glyburide—Anorexia—Dexamethasone—psoriasis	0.00011	0.000608	CcSEcCtD
Glyburide—Urticaria—Prednisolone—psoriasis	0.00011	0.000607	CcSEcCtD
Glyburide—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000109	0.000604	CcSEcCtD
Glyburide—Asthenia—Cyclosporine—psoriasis	0.000109	0.000603	CcSEcCtD
Glyburide—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.000109	0.00244	CbGpPWpGaD
Glyburide—Hypotension—Dexamethasone—psoriasis	0.000108	0.000596	CcSEcCtD
Glyburide—Hypotension—Betamethasone—psoriasis	0.000108	0.000596	CcSEcCtD
Glyburide—ABCG2—HIF-1-alpha transcription factor network—LEP—psoriasis	0.000108	0.00242	CbGpPWpGaD
Glyburide—Pruritus—Cyclosporine—psoriasis	0.000108	0.000595	CcSEcCtD
Glyburide—Urticaria—Hydrocortisone—psoriasis	0.000108	0.000593	CcSEcCtD
Glyburide—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.000107	0.0024	CbGpPWpGaD
Glyburide—Abdominal pain—Hydrocortisone—psoriasis	0.000107	0.00059	CcSEcCtD
Glyburide—Convulsion—Prednisone—psoriasis	0.000107	0.00059	CcSEcCtD
Glyburide—Asthenia—Mycophenolate mofetil—psoriasis	0.000107	0.000588	CcSEcCtD
Glyburide—Musculoskeletal discomfort—Betamethasone—psoriasis	0.000105	0.000581	CcSEcCtD
Glyburide—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.000105	0.000581	CcSEcCtD
Glyburide—Pruritus—Mycophenolate mofetil—psoriasis	0.000105	0.00058	CcSEcCtD
Glyburide—Arthralgia—Prednisone—psoriasis	0.000105	0.00058	CcSEcCtD
Glyburide—Myalgia—Prednisone—psoriasis	0.000105	0.00058	CcSEcCtD
Glyburide—Feeling abnormal—Triamcinolone—psoriasis	0.000105	0.000579	CcSEcCtD
Glyburide—Alopecia—Methotrexate—psoriasis	0.000105	0.000578	CcSEcCtD
Glyburide—Diarrhoea—Cyclosporine—psoriasis	0.000104	0.000575	CcSEcCtD
Glyburide—Paraesthesia—Betamethasone—psoriasis	0.000104	0.000573	CcSEcCtD
Glyburide—Paraesthesia—Dexamethasone—psoriasis	0.000104	0.000573	CcSEcCtD
Glyburide—CPT1A—SIDS Susceptibility Pathways—JUN—psoriasis	0.000104	0.00233	CbGpPWpGaD
Glyburide—Malnutrition—Methotrexate—psoriasis	0.000103	0.000569	CcSEcCtD
Glyburide—Erythema—Methotrexate—psoriasis	0.000103	0.000569	CcSEcCtD
Glyburide—Hypersensitivity—Prednisolone—psoriasis	0.000102	0.000563	CcSEcCtD
Glyburide—ALB—Hemostasis—SERPINB8—psoriasis	0.000102	0.00229	CbGpPWpGaD
Glyburide—Dyspepsia—Betamethasone—psoriasis	0.000102	0.000562	CcSEcCtD
Glyburide—Dyspepsia—Dexamethasone—psoriasis	0.000102	0.000562	CcSEcCtD
Glyburide—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000102	0.000561	CcSEcCtD
Glyburide—Urticaria—Triamcinolone—psoriasis	0.000101	0.000559	CcSEcCtD
Glyburide—Oedema—Prednisone—psoriasis	0.000101	0.000556	CcSEcCtD
Glyburide—ABCG2—HIF-1-alpha transcription factor network—NOS2—psoriasis	0.000101	0.00226	CbGpPWpGaD
Glyburide—Decreased appetite—Betamethasone—psoriasis	0.000101	0.000555	CcSEcCtD
Glyburide—Decreased appetite—Dexamethasone—psoriasis	0.000101	0.000555	CcSEcCtD
Glyburide—CPT1A—SIDS Susceptibility Pathways—NFKB1—psoriasis	9.99e-05	0.00224	CbGpPWpGaD
Glyburide—SLCO1A2—SLC-mediated transmembrane transport—CP—psoriasis	9.98e-05	0.00224	CbGpPWpGaD
Glyburide—Gastrointestinal disorder—Dexamethasone—psoriasis	9.98e-05	0.000551	CcSEcCtD
Glyburide—Gastrointestinal disorder—Betamethasone—psoriasis	9.98e-05	0.000551	CcSEcCtD
Glyburide—Hypersensitivity—Hydrocortisone—psoriasis	9.97e-05	0.00055	CcSEcCtD
Glyburide—ABCA1—Selenium Micronutrient Network—IL6—psoriasis	9.92e-05	0.00223	CbGpPWpGaD
Glyburide—Shock—Prednisone—psoriasis	9.91e-05	0.000547	CcSEcCtD
Glyburide—ABCG2—HIF-2-alpha transcription factor network—VEGFA—psoriasis	9.9e-05	0.00222	CbGpPWpGaD
Glyburide—ABCB1—Allograft Rejection—HLA-C—psoriasis	9.88e-05	0.00222	CbGpPWpGaD
Glyburide—Nervous system disorder—Prednisone—psoriasis	9.88e-05	0.000545	CcSEcCtD
Glyburide—ABCB1—Allograft Rejection—IL13—psoriasis	9.82e-05	0.0022	CbGpPWpGaD
Glyburide—ALB—Binding and Uptake of Ligands by Scavenger Receptors—APOE—psoriasis	9.75e-05	0.00219	CbGpPWpGaD
Glyburide—Hyperhidrosis—Prednisone—psoriasis	9.74e-05	0.000537	CcSEcCtD
Glyburide—Vision blurred—Methotrexate—psoriasis	9.72e-05	0.000536	CcSEcCtD
Glyburide—Asthenia—Hydrocortisone—psoriasis	9.71e-05	0.000536	CcSEcCtD
Glyburide—Vomiting—Cyclosporine—psoriasis	9.68e-05	0.000534	CcSEcCtD
Glyburide—Rash—Cyclosporine—psoriasis	9.6e-05	0.00053	CcSEcCtD
Glyburide—Anorexia—Prednisone—psoriasis	9.6e-05	0.00053	CcSEcCtD
Glyburide—Dermatitis—Cyclosporine—psoriasis	9.59e-05	0.000529	CcSEcCtD
Glyburide—Pruritus—Hydrocortisone—psoriasis	9.58e-05	0.000528	CcSEcCtD
Glyburide—Headache—Cyclosporine—psoriasis	9.54e-05	0.000526	CcSEcCtD
Glyburide—Anaemia—Methotrexate—psoriasis	9.53e-05	0.000526	CcSEcCtD
Glyburide—Feeling abnormal—Betamethasone—psoriasis	9.53e-05	0.000526	CcSEcCtD
Glyburide—Feeling abnormal—Dexamethasone—psoriasis	9.53e-05	0.000526	CcSEcCtD
Glyburide—Gastrointestinal pain—Betamethasone—psoriasis	9.46e-05	0.000522	CcSEcCtD
Glyburide—Gastrointestinal pain—Dexamethasone—psoriasis	9.46e-05	0.000522	CcSEcCtD
Glyburide—Vomiting—Mycophenolate mofetil—psoriasis	9.45e-05	0.000521	CcSEcCtD
Glyburide—Hypersensitivity—Triamcinolone—psoriasis	9.39e-05	0.000518	CcSEcCtD
Glyburide—SLC22A6—SLC-mediated transmembrane transport—CP—psoriasis	9.38e-05	0.00211	CbGpPWpGaD
Glyburide—Rash—Mycophenolate mofetil—psoriasis	9.37e-05	0.000517	CcSEcCtD
Glyburide—Dermatitis—Mycophenolate mofetil—psoriasis	9.36e-05	0.000516	CcSEcCtD
Glyburide—Headache—Mycophenolate mofetil—psoriasis	9.31e-05	0.000514	CcSEcCtD
Glyburide—Diarrhoea—Hydrocortisone—psoriasis	9.26e-05	0.000511	CcSEcCtD
Glyburide—Leukopenia—Methotrexate—psoriasis	9.23e-05	0.000509	CcSEcCtD
Glyburide—Urticaria—Dexamethasone—psoriasis	9.19e-05	0.000507	CcSEcCtD
Glyburide—Urticaria—Betamethasone—psoriasis	9.19e-05	0.000507	CcSEcCtD
Glyburide—Musculoskeletal discomfort—Prednisone—psoriasis	9.18e-05	0.000506	CcSEcCtD
Glyburide—Asthenia—Triamcinolone—psoriasis	9.14e-05	0.000505	CcSEcCtD
Glyburide—Abdominal pain—Dexamethasone—psoriasis	9.14e-05	0.000504	CcSEcCtD
Glyburide—Abdominal pain—Betamethasone—psoriasis	9.14e-05	0.000504	CcSEcCtD
Glyburide—CPT1A—SIDS Susceptibility Pathways—VEGFA—psoriasis	9.07e-05	0.00204	CbGpPWpGaD
Glyburide—Nausea—Cyclosporine—psoriasis	9.05e-05	0.000499	CcSEcCtD
Glyburide—Paraesthesia—Prednisone—psoriasis	9.04e-05	0.000499	CcSEcCtD
Glyburide—ABCB1—Allograft Rejection—IL17A—psoriasis	9.04e-05	0.00203	CbGpPWpGaD
Glyburide—Pruritus—Triamcinolone—psoriasis	9.02e-05	0.000498	CcSEcCtD
Glyburide—Convulsion—Methotrexate—psoriasis	8.94e-05	0.000493	CcSEcCtD
Glyburide—Dyspepsia—Prednisone—psoriasis	8.86e-05	0.000489	CcSEcCtD
Glyburide—Nausea—Mycophenolate mofetil—psoriasis	8.82e-05	0.000487	CcSEcCtD
Glyburide—Arthralgia—Methotrexate—psoriasis	8.78e-05	0.000484	CcSEcCtD
Glyburide—Myalgia—Methotrexate—psoriasis	8.78e-05	0.000484	CcSEcCtD
Glyburide—Decreased appetite—Prednisone—psoriasis	8.75e-05	0.000483	CcSEcCtD
Glyburide—Rash—Prednisolone—psoriasis	8.74e-05	0.000482	CcSEcCtD
Glyburide—Dermatitis—Prednisolone—psoriasis	8.73e-05	0.000482	CcSEcCtD
Glyburide—Headache—Prednisolone—psoriasis	8.68e-05	0.000479	CcSEcCtD
Glyburide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	8.64e-05	0.00194	CbGpPWpGaD
Glyburide—Vomiting—Hydrocortisone—psoriasis	8.61e-05	0.000475	CcSEcCtD
Glyburide—ALB—Folate Metabolism—CAT—psoriasis	8.57e-05	0.00192	CbGpPWpGaD
Glyburide—Rash—Hydrocortisone—psoriasis	8.53e-05	0.000471	CcSEcCtD
Glyburide—Dermatitis—Hydrocortisone—psoriasis	8.53e-05	0.00047	CcSEcCtD
Glyburide—Confusional state—Methotrexate—psoriasis	8.49e-05	0.000468	CcSEcCtD
Glyburide—Headache—Hydrocortisone—psoriasis	8.48e-05	0.000468	CcSEcCtD
Glyburide—CPT1A—Circadian rythm related genes—JUN—psoriasis	8.47e-05	0.0019	CbGpPWpGaD
Glyburide—ABCB1—Allograft Rejection—IL12B—psoriasis	8.4e-05	0.00189	CbGpPWpGaD
Glyburide—ALB—Vitamin B12 Metabolism—CRP—psoriasis	8.36e-05	0.00188	CbGpPWpGaD
Glyburide—ALB—Lipid and lipoprotein metabolism—APOE—psoriasis	8.32e-05	0.00187	CbGpPWpGaD
Glyburide—Feeling abnormal—Prednisone—psoriasis	8.3e-05	0.000458	CcSEcCtD
Glyburide—Asthenia—Betamethasone—psoriasis	8.3e-05	0.000458	CcSEcCtD
Glyburide—Asthenia—Dexamethasone—psoriasis	8.3e-05	0.000458	CcSEcCtD
Glyburide—ABCC8—Metabolism—NDUFA5—psoriasis	8.27e-05	0.00186	CbGpPWpGaD
Glyburide—SLCO2B1—Transmembrane transport of small molecules—CP—psoriasis	8.27e-05	0.00186	CbGpPWpGaD
Glyburide—Nervous system disorder—Methotrexate—psoriasis	8.25e-05	0.000455	CcSEcCtD
Glyburide—Thrombocytopenia—Methotrexate—psoriasis	8.24e-05	0.000455	CcSEcCtD
Glyburide—Gastrointestinal pain—Prednisone—psoriasis	8.24e-05	0.000454	CcSEcCtD
Glyburide—Nausea—Prednisolone—psoriasis	8.23e-05	0.000454	CcSEcCtD
Glyburide—ABCB1—Allograft Rejection—HLA-E—psoriasis	8.2e-05	0.00184	CbGpPWpGaD
Glyburide—ALB—Vitamin B12 Metabolism—APOE—psoriasis	8.19e-05	0.00184	CbGpPWpGaD
Glyburide—Pruritus—Dexamethasone—psoriasis	8.18e-05	0.000451	CcSEcCtD
Glyburide—Pruritus—Betamethasone—psoriasis	8.18e-05	0.000451	CcSEcCtD
Glyburide—Hyperhidrosis—Methotrexate—psoriasis	8.14e-05	0.000449	CcSEcCtD
Glyburide—Vomiting—Triamcinolone—psoriasis	8.1e-05	0.000447	CcSEcCtD
Glyburide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	8.07e-05	0.00181	CbGpPWpGaD
Glyburide—Nausea—Hydrocortisone—psoriasis	8.04e-05	0.000444	CcSEcCtD
Glyburide—Rash—Triamcinolone—psoriasis	8.04e-05	0.000443	CcSEcCtD
Glyburide—Dermatitis—Triamcinolone—psoriasis	8.03e-05	0.000443	CcSEcCtD
Glyburide—Anorexia—Methotrexate—psoriasis	8.02e-05	0.000443	CcSEcCtD
Glyburide—KCNJ11—Metabolism—NDUFA5—psoriasis	8.02e-05	0.0018	CbGpPWpGaD
Glyburide—Urticaria—Prednisone—psoriasis	8e-05	0.000441	CcSEcCtD
Glyburide—Headache—Triamcinolone—psoriasis	7.98e-05	0.000441	CcSEcCtD
Glyburide—Abdominal pain—Prednisone—psoriasis	7.96e-05	0.000439	CcSEcCtD
Glyburide—Diarrhoea—Betamethasone—psoriasis	7.91e-05	0.000437	CcSEcCtD
Glyburide—Diarrhoea—Dexamethasone—psoriasis	7.91e-05	0.000437	CcSEcCtD
Glyburide—SLCO2B1—Transmembrane transport of small molecules—CARM1—psoriasis	7.89e-05	0.00177	CbGpPWpGaD
Glyburide—ALB—Folate Metabolism—IL4—psoriasis	7.87e-05	0.00177	CbGpPWpGaD
Glyburide—Hypotension—Methotrexate—psoriasis	7.86e-05	0.000434	CcSEcCtD
Glyburide—CPT1A—SIDS Susceptibility Pathways—TNF—psoriasis	7.77e-05	0.00174	CbGpPWpGaD
Glyburide—ALB—Vitamin B12 Metabolism—ICAM1—psoriasis	7.69e-05	0.00173	CbGpPWpGaD
Glyburide—ABCC8—Transmembrane transport of small molecules—CP—psoriasis	7.69e-05	0.00173	CbGpPWpGaD
Glyburide—Musculoskeletal discomfort—Methotrexate—psoriasis	7.67e-05	0.000423	CcSEcCtD
Glyburide—ABCG2—Fluoropyrimidine Activity—TP53—psoriasis	7.66e-05	0.00172	CbGpPWpGaD
Glyburide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	7.64e-05	0.00171	CbGpPWpGaD
Glyburide—Nausea—Triamcinolone—psoriasis	7.57e-05	0.000418	CcSEcCtD
Glyburide—Paraesthesia—Methotrexate—psoriasis	7.56e-05	0.000417	CcSEcCtD
Glyburide—Dyspnoea—Methotrexate—psoriasis	7.5e-05	0.000414	CcSEcCtD
Glyburide—Hypersensitivity—Prednisone—psoriasis	7.42e-05	0.000409	CcSEcCtD
Glyburide—Dyspepsia—Methotrexate—psoriasis	7.41e-05	0.000409	CcSEcCtD
Glyburide—Vomiting—Dexamethasone—psoriasis	7.35e-05	0.000406	CcSEcCtD
Glyburide—Vomiting—Betamethasone—psoriasis	7.35e-05	0.000406	CcSEcCtD
Glyburide—ABCC8—Transmembrane transport of small molecules—CARM1—psoriasis	7.33e-05	0.00165	CbGpPWpGaD
Glyburide—Decreased appetite—Methotrexate—psoriasis	7.32e-05	0.000404	CcSEcCtD
Glyburide—Rash—Dexamethasone—psoriasis	7.29e-05	0.000402	CcSEcCtD
Glyburide—Rash—Betamethasone—psoriasis	7.29e-05	0.000402	CcSEcCtD
Glyburide—Dermatitis—Betamethasone—psoriasis	7.28e-05	0.000402	CcSEcCtD
Glyburide—Dermatitis—Dexamethasone—psoriasis	7.28e-05	0.000402	CcSEcCtD
Glyburide—Gastrointestinal disorder—Methotrexate—psoriasis	7.27e-05	0.000401	CcSEcCtD
Glyburide—Headache—Betamethasone—psoriasis	7.24e-05	0.0004	CcSEcCtD
Glyburide—Headache—Dexamethasone—psoriasis	7.24e-05	0.0004	CcSEcCtD
Glyburide—Asthenia—Prednisone—psoriasis	7.23e-05	0.000399	CcSEcCtD
Glyburide—CYP3A4—Biological oxidations—CYP2S1—psoriasis	7.16e-05	0.00161	CbGpPWpGaD
Glyburide—Pruritus—Prednisone—psoriasis	7.13e-05	0.000393	CcSEcCtD
Glyburide—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	7.06e-05	0.00158	CbGpPWpGaD
Glyburide—ABCC8—Metabolism—CYP2S1—psoriasis	7.03e-05	0.00158	CbGpPWpGaD
Glyburide—Feeling abnormal—Methotrexate—psoriasis	6.94e-05	0.000383	CcSEcCtD
Glyburide—SLC15A2—Transmembrane transport of small molecules—CP—psoriasis	6.92e-05	0.00155	CbGpPWpGaD
Glyburide—Diarrhoea—Prednisone—psoriasis	6.89e-05	0.00038	CcSEcCtD
Glyburide—Gastrointestinal pain—Methotrexate—psoriasis	6.88e-05	0.00038	CcSEcCtD
Glyburide—Nausea—Dexamethasone—psoriasis	6.87e-05	0.000379	CcSEcCtD
Glyburide—Nausea—Betamethasone—psoriasis	6.87e-05	0.000379	CcSEcCtD
Glyburide—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	6.86e-05	0.00154	CbGpPWpGaD
Glyburide—KCNJ11—Metabolism—CYP2S1—psoriasis	6.82e-05	0.00153	CbGpPWpGaD
Glyburide—ALB—Selenium Micronutrient Network—CAT—psoriasis	6.81e-05	0.00153	CbGpPWpGaD
Glyburide—ALB—Folate Metabolism—CRP—psoriasis	6.81e-05	0.00153	CbGpPWpGaD
Glyburide—SLC22A7—Transmembrane transport of small molecules—CP—psoriasis	6.8e-05	0.00153	CbGpPWpGaD
Glyburide—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	6.79e-05	0.00152	CbGpPWpGaD
Glyburide—Urticaria—Methotrexate—psoriasis	6.69e-05	0.000369	CcSEcCtD
Glyburide—ABCG2—HIF-1-alpha transcription factor network—JUN—psoriasis	6.67e-05	0.0015	CbGpPWpGaD
Glyburide—Abdominal pain—Methotrexate—psoriasis	6.65e-05	0.000367	CcSEcCtD
Glyburide—SLC15A2—Transmembrane transport of small molecules—CARM1—psoriasis	6.6e-05	0.00148	CbGpPWpGaD
Glyburide—ABCB11—Metabolism—NDUFA5—psoriasis	6.54e-05	0.00147	CbGpPWpGaD
Glyburide—SLC22A7—Transmembrane transport of small molecules—CARM1—psoriasis	6.49e-05	0.00146	CbGpPWpGaD
Glyburide—SLC15A1—Transmembrane transport of small molecules—CP—psoriasis	6.42e-05	0.00144	CbGpPWpGaD
Glyburide—Vomiting—Prednisone—psoriasis	6.4e-05	0.000353	CcSEcCtD
Glyburide—Rash—Prednisone—psoriasis	6.35e-05	0.00035	CcSEcCtD
Glyburide—Dermatitis—Prednisone—psoriasis	6.34e-05	0.00035	CcSEcCtD
Glyburide—Headache—Prednisone—psoriasis	6.31e-05	0.000348	CcSEcCtD
Glyburide—CPT1A—SIDS Susceptibility Pathways—IL6—psoriasis	6.27e-05	0.00141	CbGpPWpGaD
Glyburide—ABCC3—Metabolism—NDUFA5—psoriasis	6.27e-05	0.00141	CbGpPWpGaD
Glyburide—ALB—Folate Metabolism—ICAM1—psoriasis	6.26e-05	0.0014	CbGpPWpGaD
Glyburide—Hypersensitivity—Methotrexate—psoriasis	6.2e-05	0.000342	CcSEcCtD
Glyburide—CYP3A4—Tryptophan metabolism—CAT—psoriasis	6.18e-05	0.00139	CbGpPWpGaD
Glyburide—ABCB1—Allograft Rejection—IL10—psoriasis	6.14e-05	0.00138	CbGpPWpGaD
Glyburide—SLC15A1—Transmembrane transport of small molecules—CARM1—psoriasis	6.13e-05	0.00138	CbGpPWpGaD
Glyburide—ABCB11—Metabolism of lipids and lipoproteins—CARM1—psoriasis	6.1e-05	0.00137	CbGpPWpGaD
Glyburide—Asthenia—Methotrexate—psoriasis	6.04e-05	0.000333	CcSEcCtD
Glyburide—Nausea—Prednisone—psoriasis	5.98e-05	0.00033	CcSEcCtD
Glyburide—ABCB1—Allograft Rejection—IL4—psoriasis	5.98e-05	0.00134	CbGpPWpGaD
Glyburide—CPT1A—Metabolism of lipids and lipoproteins—APOE—psoriasis	5.97e-05	0.00134	CbGpPWpGaD
Glyburide—ABCA1—Metabolism of lipids and lipoproteins—APOE—psoriasis	5.97e-05	0.00134	CbGpPWpGaD
Glyburide—Pruritus—Methotrexate—psoriasis	5.95e-05	0.000329	CcSEcCtD
Glyburide—ALB—Vitamin B12 Metabolism—IFNG—psoriasis	5.85e-05	0.00131	CbGpPWpGaD
Glyburide—ABCC3—Metabolism of lipids and lipoproteins—CARM1—psoriasis	5.85e-05	0.00131	CbGpPWpGaD
Glyburide—ABCB1—Allograft Rejection—HLA-B—psoriasis	5.84e-05	0.00131	CbGpPWpGaD
Glyburide—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	5.84e-05	0.00131	CbGpPWpGaD
Glyburide—ABCC3—Transmembrane transport of small molecules—CP—psoriasis	5.83e-05	0.00131	CbGpPWpGaD
Glyburide—ABCG2—HIF-1-alpha transcription factor network—VEGFA—psoriasis	5.83e-05	0.00131	CbGpPWpGaD
Glyburide—Diarrhoea—Methotrexate—psoriasis	5.76e-05	0.000318	CcSEcCtD
Glyburide—CPT1A—Circadian rythm related genes—TP53—psoriasis	5.59e-05	0.00126	CbGpPWpGaD
Glyburide—CPT1A—Metabolism—CARM1—psoriasis	5.56e-05	0.00125	CbGpPWpGaD
Glyburide—ABCA1—Metabolism—CARM1—psoriasis	5.56e-05	0.00125	CbGpPWpGaD
Glyburide—ABCB11—Metabolism—CYP2S1—psoriasis	5.56e-05	0.00125	CbGpPWpGaD
Glyburide—ABCC3—Transmembrane transport of small molecules—CARM1—psoriasis	5.56e-05	0.00125	CbGpPWpGaD
Glyburide—SLCO1A2—Metabolism—NDUFA5—psoriasis	5.46e-05	0.00123	CbGpPWpGaD
Glyburide—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	5.44e-05	0.00122	CbGpPWpGaD
Glyburide—ABCB1—Allograft Rejection—HLA-A—psoriasis	5.41e-05	0.00121	CbGpPWpGaD
Glyburide—ALB—Selenium Micronutrient Network—CRP—psoriasis	5.41e-05	0.00121	CbGpPWpGaD
Glyburide—Vomiting—Methotrexate—psoriasis	5.35e-05	0.000295	CcSEcCtD
Glyburide—ABCC3—Metabolism—CYP2S1—psoriasis	5.33e-05	0.0012	CbGpPWpGaD
Glyburide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	5.32e-05	0.00119	CbGpPWpGaD
Glyburide—Rash—Methotrexate—psoriasis	5.31e-05	0.000293	CcSEcCtD
Glyburide—Dermatitis—Methotrexate—psoriasis	5.3e-05	0.000293	CcSEcCtD
Glyburide—Headache—Methotrexate—psoriasis	5.27e-05	0.000291	CcSEcCtD
Glyburide—CPT1A—Metabolism of lipids and lipoproteins—PPARG—psoriasis	5.2e-05	0.00117	CbGpPWpGaD
Glyburide—ABCA1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	5.2e-05	0.00117	CbGpPWpGaD
Glyburide—CPT1A—Circadian rythm related genes—IL6—psoriasis	5.12e-05	0.00115	CbGpPWpGaD
Glyburide—SLCO1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	5.09e-05	0.00114	CbGpPWpGaD
Glyburide—SLCO1A2—Transmembrane transport of small molecules—CP—psoriasis	5.07e-05	0.00114	CbGpPWpGaD
Glyburide—Nausea—Methotrexate—psoriasis	5e-05	0.000276	CcSEcCtD
Glyburide—ALB—Selenium Micronutrient Network—ICAM1—psoriasis	4.97e-05	0.00112	CbGpPWpGaD
Glyburide—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	4.95e-05	0.00111	CbGpPWpGaD
Glyburide—ABCC1—Metabolism—NDUFA5—psoriasis	4.91e-05	0.0011	CbGpPWpGaD
Glyburide—ALB—SLC-mediated transmembrane transport—CP—psoriasis	4.88e-05	0.00109	CbGpPWpGaD
Glyburide—ALB—Vitamin B12 Metabolism—NFKB1—psoriasis	4.87e-05	0.00109	CbGpPWpGaD
Glyburide—SLCO1A2—Transmembrane transport of small molecules—CARM1—psoriasis	4.84e-05	0.00109	CbGpPWpGaD
Glyburide—SLC22A6—Transmembrane transport of small molecules—CP—psoriasis	4.77e-05	0.00107	CbGpPWpGaD
Glyburide—ALB—Folate Metabolism—IFNG—psoriasis	4.76e-05	0.00107	CbGpPWpGaD
Glyburide—SLCO1A2—Metabolism—CYP2S1—psoriasis	4.64e-05	0.00104	CbGpPWpGaD
Glyburide—ABCC2—Transmembrane transport of small molecules—CP—psoriasis	4.62e-05	0.00104	CbGpPWpGaD
Glyburide—ABCC1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.58e-05	0.00103	CbGpPWpGaD
Glyburide—ABCC1—Transmembrane transport of small molecules—CP—psoriasis	4.57e-05	0.00102	CbGpPWpGaD
Glyburide—SLC22A6—Transmembrane transport of small molecules—CARM1—psoriasis	4.55e-05	0.00102	CbGpPWpGaD
Glyburide—ABCC2—Transmembrane transport of small molecules—CARM1—psoriasis	4.41e-05	0.000989	CbGpPWpGaD
Glyburide—ABCC1—Transmembrane transport of small molecules—CARM1—psoriasis	4.36e-05	0.000977	CbGpPWpGaD
Glyburide—ABCG2—Metabolism—NDUFA5—psoriasis	4.32e-05	0.00097	CbGpPWpGaD
Glyburide—ABCC1—Metabolism—CYP2S1—psoriasis	4.18e-05	0.000937	CbGpPWpGaD
Glyburide—ABCG2—Transmembrane transport of small molecules—CP—psoriasis	4.02e-05	0.000902	CbGpPWpGaD
Glyburide—ALB—Folate Metabolism—NFKB1—psoriasis	3.96e-05	0.000889	CbGpPWpGaD
Glyburide—ABCG2—Transmembrane transport of small molecules—CARM1—psoriasis	3.83e-05	0.00086	CbGpPWpGaD
Glyburide—ALB—Vitamin B12 Metabolism—TNF—psoriasis	3.79e-05	0.00085	CbGpPWpGaD
Glyburide—ALB—Selenium Micronutrient Network—IFNG—psoriasis	3.78e-05	0.000849	CbGpPWpGaD
Glyburide—ABCG2—Metabolism—CYP2S1—psoriasis	3.68e-05	0.000825	CbGpPWpGaD
Glyburide—ABCB1—Allograft Rejection—IFNG—psoriasis	3.61e-05	0.000811	CbGpPWpGaD
Glyburide—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	3.61e-05	0.000809	CbGpPWpGaD
Glyburide—ABCC8—Metabolism—CARM1—psoriasis	3.44e-05	0.000771	CbGpPWpGaD
Glyburide—CPT1A—Metabolism—CAT—psoriasis	3.42e-05	0.000768	CbGpPWpGaD
Glyburide—ABCA1—Metabolism—CAT—psoriasis	3.42e-05	0.000768	CbGpPWpGaD
Glyburide—ABCB1—Allograft Rejection—CXCL8—psoriasis	3.36e-05	0.000754	CbGpPWpGaD
Glyburide—KCNJ11—Metabolism—CARM1—psoriasis	3.33e-05	0.000748	CbGpPWpGaD
Glyburide—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	3.15e-05	0.000707	CbGpPWpGaD
Glyburide—ALB—Selenium Micronutrient Network—NFKB1—psoriasis	3.15e-05	0.000706	CbGpPWpGaD
Glyburide—ALB—Platelet degranulation—VEGFA—psoriasis	3.08e-05	0.000692	CbGpPWpGaD
Glyburide—ALB—Folate Metabolism—TNF—psoriasis	3.08e-05	0.000691	CbGpPWpGaD
Glyburide—ALB—Vitamin B12 Metabolism—IL6—psoriasis	3.06e-05	0.000686	CbGpPWpGaD
Glyburide—ALB—Hemostasis—ITGAL—psoriasis	2.97e-05	0.000665	CbGpPWpGaD
Glyburide—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—psoriasis	2.94e-05	0.000659	CbGpPWpGaD
Glyburide—ABCB11—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.91e-05	0.000654	CbGpPWpGaD
Glyburide—ABCC3—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.79e-05	0.000627	CbGpPWpGaD
Glyburide—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	2.77e-05	0.000621	CbGpPWpGaD
Glyburide—ABCB1—Allograft Rejection—VEGFA—psoriasis	2.73e-05	0.000612	CbGpPWpGaD
Glyburide—ALB—Folate Metabolism—TP53—psoriasis	2.72e-05	0.00061	CbGpPWpGaD
Glyburide—ABCB11—Metabolism—CARM1—psoriasis	2.72e-05	0.000609	CbGpPWpGaD
Glyburide—ALB—Metabolism—NDUFA5—psoriasis	2.67e-05	0.000599	CbGpPWpGaD
Glyburide—CPT1A—Metabolism—APOE—psoriasis	2.66e-05	0.000596	CbGpPWpGaD
Glyburide—ABCA1—Metabolism—APOE—psoriasis	2.66e-05	0.000596	CbGpPWpGaD
Glyburide—ABCC3—Metabolism—CARM1—psoriasis	2.6e-05	0.000584	CbGpPWpGaD
Glyburide—ABCB11—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.54e-05	0.00057	CbGpPWpGaD
Glyburide—ALB—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.49e-05	0.000558	CbGpPWpGaD
Glyburide—ALB—Folate Metabolism—IL6—psoriasis	2.49e-05	0.000558	CbGpPWpGaD
Glyburide—ALB—Transmembrane transport of small molecules—CP—psoriasis	2.48e-05	0.000556	CbGpPWpGaD
Glyburide—ALB—Selenium Micronutrient Network—TNF—psoriasis	2.45e-05	0.000549	CbGpPWpGaD
Glyburide—ABCC3—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.43e-05	0.000546	CbGpPWpGaD
Glyburide—SLCO1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.43e-05	0.000546	CbGpPWpGaD
Glyburide—CYP2C19—Metabolism—NDUFA5—psoriasis	2.39e-05	0.000537	CbGpPWpGaD
Glyburide—ALB—Transmembrane transport of small molecules—CARM1—psoriasis	2.36e-05	0.000531	CbGpPWpGaD
Glyburide—ABCB1—Allograft Rejection—TNF—psoriasis	2.34e-05	0.000525	CbGpPWpGaD
Glyburide—ABCB1—Metabolism—NDUFA5—psoriasis	2.34e-05	0.000525	CbGpPWpGaD
Glyburide—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	2.32e-05	0.000522	CbGpPWpGaD
Glyburide—ABCA1—Metabolism—PPARG—psoriasis	2.31e-05	0.000519	CbGpPWpGaD
Glyburide—CPT1A—Metabolism—PPARG—psoriasis	2.31e-05	0.000519	CbGpPWpGaD
Glyburide—ALB—Metabolism—CYP2S1—psoriasis	2.27e-05	0.000509	CbGpPWpGaD
Glyburide—SLCO1A2—Metabolism—CARM1—psoriasis	2.27e-05	0.000509	CbGpPWpGaD
Glyburide—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.23e-05	0.000501	CbGpPWpGaD
Glyburide—ABCC1—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.19e-05	0.000491	CbGpPWpGaD
Glyburide—CYP2C9—Metabolism—NDUFA5—psoriasis	2.18e-05	0.00049	CbGpPWpGaD
Glyburide—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	2.17e-05	0.000487	CbGpPWpGaD
Glyburide—SLCO1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.12e-05	0.000476	CbGpPWpGaD
Glyburide—ABCC8—Metabolism—CAT—psoriasis	2.11e-05	0.000474	CbGpPWpGaD
Glyburide—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	2.07e-05	0.000465	CbGpPWpGaD
Glyburide—KCNJ11—Metabolism—CAT—psoriasis	2.05e-05	0.00046	CbGpPWpGaD
Glyburide—ABCC1—Metabolism—CARM1—psoriasis	2.04e-05	0.000458	CbGpPWpGaD
Glyburide—CYP2C19—Metabolism—CYP2S1—psoriasis	2.04e-05	0.000457	CbGpPWpGaD
Glyburide—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.04e-05	0.000457	CbGpPWpGaD
Glyburide—ABCB1—Metabolism—CYP2S1—psoriasis	1.99e-05	0.000446	CbGpPWpGaD
Glyburide—ALB—Selenium Micronutrient Network—IL6—psoriasis	1.98e-05	0.000443	CbGpPWpGaD
Glyburide—ABCC1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.91e-05	0.000428	CbGpPWpGaD
Glyburide—CYP2C9—Metabolism—CYP2S1—psoriasis	1.86e-05	0.000417	CbGpPWpGaD
Glyburide—ABCG2—Metabolism—CARM1—psoriasis	1.79e-05	0.000403	CbGpPWpGaD
Glyburide—ABCB11—Metabolism—CAT—psoriasis	1.67e-05	0.000375	CbGpPWpGaD
Glyburide—ABCC8—Metabolism—APOE—psoriasis	1.64e-05	0.000368	CbGpPWpGaD
Glyburide—ABCC3—Metabolism—CAT—psoriasis	1.6e-05	0.000359	CbGpPWpGaD
Glyburide—KCNJ11—Metabolism—APOE—psoriasis	1.59e-05	0.000357	CbGpPWpGaD
Glyburide—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.54e-05	0.000346	CbGpPWpGaD
Glyburide—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.48e-05	0.000333	CbGpPWpGaD
Glyburide—CYP3A4—Metabolism—NDUFA5—psoriasis	1.44e-05	0.000323	CbGpPWpGaD
Glyburide—ABCC8—Metabolism—PPARG—psoriasis	1.43e-05	0.000321	CbGpPWpGaD
Glyburide—SLCO1A2—Metabolism—CAT—psoriasis	1.39e-05	0.000313	CbGpPWpGaD
Glyburide—KCNJ11—Metabolism—PPARG—psoriasis	1.39e-05	0.000311	CbGpPWpGaD
Glyburide—ALB—Platelet activation, signaling and aggregation—VEGFA—psoriasis	1.37e-05	0.000307	CbGpPWpGaD
Glyburide—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.35e-05	0.000302	CbGpPWpGaD
Glyburide—ABCB11—Metabolism—APOE—psoriasis	1.3e-05	0.000291	CbGpPWpGaD
Glyburide—ABCC1—Metabolism—CAT—psoriasis	1.25e-05	0.000282	CbGpPWpGaD
Glyburide—ABCC1—Disease—HLA-A—psoriasis	1.25e-05	0.00028	CbGpPWpGaD
Glyburide—ABCC3—Metabolism—APOE—psoriasis	1.24e-05	0.000279	CbGpPWpGaD
Glyburide—CYP3A4—Metabolism—CYP2S1—psoriasis	1.22e-05	0.000275	CbGpPWpGaD
Glyburide—ALB—Hemostasis—NOS2—psoriasis	1.22e-05	0.000273	CbGpPWpGaD
Glyburide—ALB—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.19e-05	0.000267	CbGpPWpGaD
Glyburide—ABCC1—Disease—APOE—psoriasis	1.16e-05	0.000261	CbGpPWpGaD
Glyburide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.15e-05	0.000259	CbGpPWpGaD
Glyburide—ABCB11—Metabolism—PPARG—psoriasis	1.13e-05	0.000254	CbGpPWpGaD
Glyburide—ALB—Metabolism—CARM1—psoriasis	1.11e-05	0.000249	CbGpPWpGaD
Glyburide—ABCG2—Metabolism—CAT—psoriasis	1.1e-05	0.000248	CbGpPWpGaD
Glyburide—ABCC1—Disease—NOS2—psoriasis	1.08e-05	0.000243	CbGpPWpGaD
Glyburide—ABCC3—Metabolism—PPARG—psoriasis	1.08e-05	0.000243	CbGpPWpGaD
Glyburide—SLCO1A2—Metabolism—APOE—psoriasis	1.08e-05	0.000243	CbGpPWpGaD
Glyburide—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.07e-05	0.000239	CbGpPWpGaD
Glyburide—ALB—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.04e-05	0.000232	CbGpPWpGaD
Glyburide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.02e-05	0.000228	CbGpPWpGaD
Glyburide—CYP2C19—Metabolism—CARM1—psoriasis	9.94e-06	0.000223	CbGpPWpGaD
Glyburide—ABCC1—Metabolism—APOE—psoriasis	9.75e-06	0.000219	CbGpPWpGaD
Glyburide—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	9.73e-06	0.000218	CbGpPWpGaD
Glyburide—ABCB1—Metabolism—CARM1—psoriasis	9.7e-06	0.000218	CbGpPWpGaD
Glyburide—SLCO1A2—Metabolism—PPARG—psoriasis	9.44e-06	0.000212	CbGpPWpGaD
Glyburide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	9.29e-06	0.000209	CbGpPWpGaD
Glyburide—CYP2C9—Metabolism—CARM1—psoriasis	9.07e-06	0.000203	CbGpPWpGaD
Glyburide—ABCC1—Disease—TYK2—psoriasis	8.88e-06	0.000199	CbGpPWpGaD
Glyburide—ABCG2—Metabolism—APOE—psoriasis	8.58e-06	0.000193	CbGpPWpGaD
Glyburide—ABCC1—Metabolism—PPARG—psoriasis	8.49e-06	0.000191	CbGpPWpGaD
Glyburide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.47e-06	0.00019	CbGpPWpGaD
Glyburide—ABCC1—Disease—CD4—psoriasis	8.04e-06	0.00018	CbGpPWpGaD
Glyburide—ABCG2—Metabolism—PPARG—psoriasis	7.47e-06	0.000168	CbGpPWpGaD
Glyburide—ALB—Hemostasis—VEGFA—psoriasis	7.05e-06	0.000158	CbGpPWpGaD
Glyburide—ALB—Metabolism—CAT—psoriasis	6.81e-06	0.000153	CbGpPWpGaD
Glyburide—ABCC1—Disease—STAT3—psoriasis	6.22e-06	0.00014	CbGpPWpGaD
Glyburide—CYP2C19—Metabolism—CAT—psoriasis	6.12e-06	0.000137	CbGpPWpGaD
Glyburide—CYP3A4—Metabolism—CARM1—psoriasis	5.98e-06	0.000134	CbGpPWpGaD
Glyburide—ABCB1—Metabolism—CAT—psoriasis	5.97e-06	0.000134	CbGpPWpGaD
Glyburide—CYP2C9—Metabolism—CAT—psoriasis	5.58e-06	0.000125	CbGpPWpGaD
Glyburide—ALB—Hemostasis—TP53—psoriasis	5.32e-06	0.000119	CbGpPWpGaD
Glyburide—ALB—Metabolism—APOE—psoriasis	5.29e-06	0.000119	CbGpPWpGaD
Glyburide—CYP2C19—Metabolism—APOE—psoriasis	4.75e-06	0.000107	CbGpPWpGaD
Glyburide—ABCB1—Metabolism—APOE—psoriasis	4.64e-06	0.000104	CbGpPWpGaD
Glyburide—ALB—Metabolism—PPARG—psoriasis	4.61e-06	0.000103	CbGpPWpGaD
Glyburide—ABCC1—Disease—IL6—psoriasis	4.35e-06	9.75e-05	CbGpPWpGaD
Glyburide—CYP2C9—Metabolism—APOE—psoriasis	4.33e-06	9.72e-05	CbGpPWpGaD
Glyburide—CYP2C19—Metabolism—PPARG—psoriasis	4.14e-06	9.29e-05	CbGpPWpGaD
Glyburide—ABCB1—Metabolism—PPARG—psoriasis	4.04e-06	9.07e-05	CbGpPWpGaD
Glyburide—CYP2C9—Metabolism—PPARG—psoriasis	3.77e-06	8.47e-05	CbGpPWpGaD
Glyburide—CYP3A4—Metabolism—CAT—psoriasis	3.68e-06	8.25e-05	CbGpPWpGaD
Glyburide—CYP3A4—Metabolism—APOE—psoriasis	2.86e-06	6.41e-05	CbGpPWpGaD
Glyburide—CYP3A4—Metabolism—PPARG—psoriasis	2.49e-06	5.59e-05	CbGpPWpGaD
